These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome. Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP Urol Clin North Am; 2007 May; 34(2):219-25; abstract ix-x. PubMed ID: 17484926 [TBL] [Abstract][Full Text] [Related]
3. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534 [TBL] [Abstract][Full Text] [Related]
4. Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. Ong TA; Winkler MH; Savage PM; Seckl MJ; Christmas TJ BJU Int; 2008 Jul; 102(2):198-202. PubMed ID: 18294302 [TBL] [Abstract][Full Text] [Related]
5. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541 [TBL] [Abstract][Full Text] [Related]
6. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors. Beck SD; Foster RS; Bihrle R; Donohue JP Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165 [TBL] [Abstract][Full Text] [Related]
7. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916 [TBL] [Abstract][Full Text] [Related]
8. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors. Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392 [TBL] [Abstract][Full Text] [Related]
9. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers. Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879 [TBL] [Abstract][Full Text] [Related]
10. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730 [TBL] [Abstract][Full Text] [Related]
11. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432 [TBL] [Abstract][Full Text] [Related]
19. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854 [TBL] [Abstract][Full Text] [Related]
20. Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein. Peterson M; Beck S; Bihrle R; Einhorn L; Foster R BJU Int; 2009 Jul; 104(2):176-8. PubMed ID: 19493258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]